| Company Name: |
BOC Sciences |
| Tel: |
16314854226 |
| Email: |
inquiry@bocsci.com |
6-Amino-2,5-dihydro-2-(-D-ribofuranosyl)-4H-pyrazolo[3,4-d]pyrimidin-4-one manufacturers
|
| | 6-Amino-2,5-dihydro-2-(-D-ribofuranosyl)-4H-pyrazolo[3,4-d]pyrimidin-4-one Basic information |
| Product Name: | 6-Amino-2,5-dihydro-2-(-D-ribofuranosyl)-4H-pyrazolo[3,4-d]pyrimidin-4-one | | Synonyms: | 6-Amino-2,5-dihydro-2-(-D-ribofuranosyl)-4H-pyrazolo[3,4-d]pyrimidin-4-one;6-Amino-2,5-dihydro-2-(beta-D-ribofuranosyl)-4H-pyrazolo[3,4-d]pyrimidin-4-one;6-Amino-2,5-dihydro-2-(b-D-ribofuranosyl)-4H-pyrazolo[3,4-d]pyrimidin-4-one;4H-Pyrazolo[3,4-d]pyrimidin-4-one, 6-amino-1,2-dihydro-2-β-D-ribofuranosyl-;6-amino-2-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one;6-Amino-2,5-dihydro-2-(β-D-ribofuranosyl)-4H-pyrazolo[3,4-d]pyrimidin-4-one | | CAS: | 85426-86-4 | | MF: | C10H13N5O5 | | MW: | 283.24072 | | EINECS: | | | Product Categories: | | | Mol File: | 85426-86-4.mol | ![6-Amino-2,5-dihydro-2-(-D-ribofuranosyl)-4H-pyrazolo[3,4-d]pyrimidin-4-one Structure](CAS/20180703/GIF/85426-86-4.gif) |
| | 6-Amino-2,5-dihydro-2-(-D-ribofuranosyl)-4H-pyrazolo[3,4-d]pyrimidin-4-one Chemical Properties |
| density | 2.25±0.1 g/cm3(Predicted) | | pka | 7.99±0.20(Predicted) |
| | 6-Amino-2,5-dihydro-2-(-D-ribofuranosyl)-4H-pyrazolo[3,4-d]pyrimidin-4-one Usage And Synthesis |
| Uses | 6-Amino-1,2-dihydro-2-β-D-ribofuranosyl-4H-pyrazolo[3,4-d]pyrimidin-4-one is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
| | 6-Amino-2,5-dihydro-2-(-D-ribofuranosyl)-4H-pyrazolo[3,4-d]pyrimidin-4-one Preparation Products And Raw materials |
|